Analysts Issue Forecasts for CMPS Q1 Earnings

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) – Equities researchers at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Compass Pathways in a research report issued on Wednesday, March 25th. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings per share of ($0.35) for the quarter. HC Wainwright currently has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Compass Pathways’ current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for Compass Pathways’ Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.48) EPS, FY2026 earnings at ($1.66) EPS and FY2027 earnings at ($0.96) EPS.

Compass Pathways (NASDAQ:CMPS) last released its quarterly earnings data on Tuesday, March 24th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.59).

Several other research analysts have also weighed in on CMPS. Royal Bank Of Canada boosted their price target on Compass Pathways from $21.00 to $22.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 18th. Lifesci Capital raised Compass Pathways to a “strong-buy” rating in a report on Thursday, February 12th. Morgan Stanley lowered their target price on shares of Compass Pathways from $18.00 to $16.00 and set an “overweight” rating on the stock in a report on Wednesday. Canaccord Genuity Group dropped their price target on shares of Compass Pathways from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, Compass Point set a $15.00 price target on shares of Compass Pathways in a research note on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Compass Pathways currently has an average rating of “Moderate Buy” and a consensus target price of $21.63.

Compass Pathways Stock Down 4.8%

Shares of CMPS stock opened at $5.37 on Friday. The stock has a fifty day moving average price of $6.66 and a 200 day moving average price of $6.30. Compass Pathways has a one year low of $2.25 and a one year high of $8.90. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.77 and a quick ratio of 1.23. The stock has a market cap of $515.63 million, a P/E ratio of -1.74 and a beta of 1.90.

Institutional Trading of Compass Pathways

A number of hedge funds have recently made changes to their positions in CMPS. Corient Private Wealth LLC raised its holdings in shares of Compass Pathways by 3.2% during the 4th quarter. Corient Private Wealth LLC now owns 38,438 shares of the company’s stock worth $265,000 after buying an additional 1,200 shares in the last quarter. CWM LLC boosted its position in Compass Pathways by 19.2% in the third quarter. CWM LLC now owns 15,650 shares of the company’s stock valued at $90,000 after buying an additional 2,525 shares in the last quarter. Conservest Capital Advisors Inc. increased its holdings in shares of Compass Pathways by 24.6% during the fourth quarter. Conservest Capital Advisors Inc. now owns 25,363 shares of the company’s stock worth $175,000 after buying an additional 5,000 shares in the last quarter. Persistent Asset Partners Ltd acquired a new stake in shares of Compass Pathways during the 4th quarter valued at $38,000. Finally, China Universal Asset Management Co. Ltd. grew its position in Compass Pathways by 46.7% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 18,272 shares of the company’s stock worth $51,000 after acquiring an additional 5,817 shares during the last quarter. 46.19% of the stock is owned by institutional investors and hedge funds.

More Compass Pathways News

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating with a very high $70 price target, signaling a strong long‑term bullish case and large implied upside versus the current share price. (This supports investor optimism even as near‑term forecasts were adjusted.)
• Neutral Sentiment: Upcoming FDA review meeting for COMP360 is a potential binary catalyst — outcomes or guidance from that meeting could swing sentiment materially in either direction. Compass Pathways (CMPS): What will come out of FDA review meeting for depression drug candidate COMP360?
• Neutral Sentiment: Canaccord cut its price target from $20 to $18 but kept a “Buy” rating — a modest downgrade that still implies significant upside from current levels. Canaccord target cut report
• Negative Sentiment: HC Wainwright lowered its FY2026 EPS forecast to ($1.66) from ($1.36) and cut FY2027 to ($0.96) (previously $0.72), and issued lower quarterly EPS estimates across 2026–2027 — firms’ reduced profit outlook increases short‑term pressure on the share price.
• Negative Sentiment: Morgan Stanley trimmed its price target to $16, which reduces near‑term upside and may prompt short‑term selling. Morgan Stanley Lowers Compass Pathways (NASDAQ:CMPS) Price Target to $16.00
• Negative Sentiment: Recent earnings (reported 3/24) missed estimates (EPS -$1.00 vs. consensus -$0.41), reinforcing concerns on near‑term profitability and contributing to downward pressure on the stock.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.